SRNE — Sorrento Therape

Sorrento Therape (SRNE) is a biotechnology company listed on OTCQB. It is led by Henry H. Ji Ph.D., based in 4955 Directors Place, San Diego, CA, United States, 92121, with about 949 employees. Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Net income was -$108.5M. SRNE currently screens at market cap $385.9K.

Use this SRNE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SRNE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SRNE SEC filings page. Lician reads the product cache first so this HTML stays unique to Sorrento Therape even when a live quote feed is slow.